Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Continuous Renal Replacement Therapy
NCT ID: NCT02423642
Last Updated: 2021-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2013-07-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Citrate Versus Heparin in Continuous Renal Replacement Therapy :
NCT04865510
Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy
NCT01269112
Effect of Citrate on the Coagulation System in Patients Receiving CRRT
NCT02486614
Investigating Different Anticoagulants for Renal Replacement Therapy
NCT02669589
Outcomes of Critically Ill Patients Undergoing RRT- a Registry Based Study.
NCT06897254
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AKI requring CRRT and use regional citrate anticoagulation
CRRT use regional citrate anticoagulation
Continuous renal replacement therapy with regional citrate anticoagulation
CRRT with anticoagulant : regional citrate anticoagulation
Filter : AQUAMAX™ (Edwards Lifesciences)
AKI requring CRRT and not use regional citrate anticoagulation
CRRT not use regional citrate anticoagulation
Continuous renal replacement therapy with no anticoagulation or heparin
CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continuous renal replacement therapy with regional citrate anticoagulation
CRRT with anticoagulant : regional citrate anticoagulation
Filter : AQUAMAX™ (Edwards Lifesciences)
Continuous renal replacement therapy with no anticoagulation or heparin
CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with acute kidney injury in the intensive care ward.
* Requiring continuous renal replacement therapy.
Exclusion Criteria
* Cirrhosis
* End stage renal disease
* HIV infection
* Serum creatinine in male \> 2 mg/dl and female \> 1.5 mg/dl
* Bleeding
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nattachai Srisawat ,M.D.
Division of Nephrology, Department of Medicine, Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sasipha Tachaboon
Bangkok, Pathumwan, Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB.136/56
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.